MedTrace Logo

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

NCT00258960 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-04-04

Study results available
· View outcomes & findings →

Summary

Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.

Conditions

Interventions

DRUG

Liposomal Doxorubicin

DRUG

Cyclophosphamide

DRUG

Trastuzumab

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Spanish Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Study Director · Hospital Clínico Universitario San Carlos

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-15
Primary Completion
2008-07-31
Completion
2009-07-14

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00258960 on ClinicalTrials.gov